Methamphetamine neurotoxicity, microglia, and neuroinflammation

This paper provides a critical neuropathological review of the relationship between methamphetamine (METH) exposure, microglial activation, and neuroinflammation. While METH is well-known for its neurotoxic effects on the dopaminergic system, a common narrative in the field suggests that microglia-driven neuroinflammation acts as a primary mechanism that worsens METH-induced damage. The authors revisit this hypothesis by evaluating histopathological evidence from rodent studies, shifting the focus from biochemical assays to direct morphological and immunophenotypic observations of microglial cells.

Through an analysis of existing literature, the authors argue that microglia act as sensors of pathology rather than instigators of neuronal damage. In the nigrostriatal dopaminergic system, METH exposure typically results in only mild microglial activation, which the authors characterize as a repair-oriented response to neuronal perturbation. The authors emphasize that microglial responses are often secondary to vascular damage and blood-brain barrier (BBB) compromise, particularly under conditions of hyperthermia, rather than a direct, toxic effect of METH on microglia itself.

The study concludes that there is little evidence to support the use of anti-inflammatory agents as a treatment for METH addiction. If the observed neuroinflammation is merely a consequence of previous neuronal or vascular injury, suppressing it would not address the underlying pathology or the addictive process. The authors call for a reassessment of the therapeutic goals in addiction research, suggesting that focus should shift away from suppressing immune responses toward understanding the initial neurotoxic and vascular triggers caused by METH.